Table 3.
Clinicopathological Characteristics of 258 Patients Undergoing Neoadjuvant Chemotherapy
| Characteristics | n (%) (258, 100%) | Good Responder (n=215) | Poor Responder (n=43) | P |
|---|---|---|---|---|
| Age | 0.955 | |||
| <50 | 115 (44.6) | 96 (44.7) | 19 (44.2) | |
| ≥50 | 143 (55.4) | 119 (55.3) | 24 (55.8) | |
| BMI | 0.029 | |||
| <25 | 180 (69.8) | 156 (72.6) | 24 (55.8) | |
| ≥25 | 78 (30.2) | 59 (27.4) | 19 (44.2) | |
| Menstrual status | 1.000 | |||
| Premenopausal | 132 (51.2) | 110 (51.2) | 22 (51.2) | |
| Postmenopausal | 126 (48.8) | 105 (48.8) | 21 (48.8) | |
| Tumor T stage | 0.017 | |||
| T1-3 | 240 (93.0) | 204 (94.9) | 36 (83.7) | |
| T4 | 18 (7.0) | 11 (5.1) | 7 (16.3) | |
| Lymph node involvement | 1.000 | |||
| No | 30 (11.6) | 25 (11.6) | 5 (11.6) | |
| Yes | 228 (88.4) | 190 (88.4) | 38 (88.4) | |
| Lesion | 0.701 | |||
| Single focal | 245 (95.0) | 203 (94.4) | 42 (97.7) | |
| Multifocal | 13 (5.0) | 12 (5.6) | 1 (2.3) | |
| AJCC stagea | 0.093 | |||
| Stage II–III | 251 (97.3) | 211 (98.1) | 40 (93.0) | |
| Stage IV | 7 (2.7) | 4 (1.9) | 3 (7.0) | |
| Histological type | 0.009 | |||
| Unspecified or others | 131 (50.8) | 117 (54.4) | 14 (32.6) | |
| IDC | 127 (49.2) | 98 (45.6) | 29 (67.4) | |
| ER status | 0.082 | |||
| Negative | 115 (44.6) | 101 (47.3) | 14 (32.6) | |
| Positive | 143 (55.4) | 114 (53.0) | 29 (67.4) | |
| PR status | 0.009 | |||
| Negative | 125 (48.4) | 112 (52.1) | 13 (30.2) | |
| Positive | 133 (51.6) | 103 (47.9) | 30 (69.8) | |
| Ki-67 | 0.028 | |||
| <14% | 38 (14.7) | 27 (12.6) | 11 (25.6) | |
| ≥14% | 220 (85.3) | 188 (87.4) | 32 (74.4) | |
| HER2 status | 0.000 | |||
| Negative | 133 (51.6) | 100 (46.5) | 33 (76.7) | |
| Positive | 125 (48.4) | 115 (53.5) | 10 (23.3) | |
| Molecular subtype | 0.001 | |||
| HR+HER2- | 94 (36.4) | 68 (31.6) | 26 (60.5) | |
| TNBC | 39 (15.1) | 32 (14.9) | 7 (16.3) | |
| HR-HER2+ | 55 (21.3) | 52 (24.2) | 3 (7.0) | |
| HR+HER2+ | 70 (27.1) | 63 (29.3) | 7 (16.3) | |
| Neoadjuvant chemotherapy regimen | 0.224 | |||
| Anthracycline-based | 16 (6.2) | 13 (6.0) | 3 (7.0) | |
| Taxane-based | 55 (21.3) | 50 (23.3) | 5 (11.6) | |
| Combination | 187 (72.5) | 152 (70.7) | 35 (81.4) | |
| Chemotherapy cycle | 0.530 | |||
| ≤6 | 101 (39.1) | 86 (40.0) | 15 (34.9) | |
| >6 | 157 (60.9) | 129 (60.0) | 28 (65.1) | |
| NLR | 0.122 | |||
| <1.77 | 73 (28.3) | 65 (30.2) | 8 (18.6) | |
| ≥1.77 | 185 (71.7) | 150 (69.8) | 35 (81.4) | |
| PLR | 0.126 | |||
| <137 | 153 (59.3) | 132 (61.4) | 21 (48.8) | |
| ≥137 | 105 (40.7) | 83 (38.6) | 22 (51.2) | |
| SII | 0.020 | |||
| <586.40 | 155 (60.1) | 136 (63.3) | 19 (44.2) | |
| ≥586.40 | 103 (39.9) | 79 (36.7) | 24 (55.8) | |
| Neutrophil count | 0.065 | |||
| Median [IQR] | 4.00 [3.01–4.91] | 4.08 [3.50–5.63] | ||
| Platelet count | 0.005 | |||
| Median [IQR] | 225 [192–267] | 266 [213–326] | ||
| Lymphocyte count | 0.732 | |||
| Median [IQR] | 1.80 [1.41–2.13] | 1.78 [1.31–2.41] |
Notes: a7 (2.7%) patients with oligometastasis undergoing “neoadjuvant chemotherapy” before the palliative operation were also analyzed for the relationship between AJCC stage and chemotherapy reaction (here only refers to the local reaction of the breast). P: p-value, bold p-value indicated a statistical difference.
Abbreviations: BMI, body mass index; AJCC, American Joint Committee on Cancer; IDC, invasive ductal carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; HR, hormone receptor; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammation index; IQR, interquartile range.